[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$ffCMP83_uLo-t8k2LDXxsgRdY8IDruQPnVugAgpimZWk":8,"$fvhLG2yeRRPgan-AkLnWiU6bMTxk-p8M6DHtfkoRUGi4":55,"$fPg9g-v7epTtLcr9RqQqOMGYD4Goc6dhtMJkUH_utKMc":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},66504,869460,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//oxzyB6fWPWB6dtH5WvFkMh8jEI76jIwG.png","田彦华","树兰（杭州）医院","皮肤性病科","主治医师",35,0,"黑色素瘤术后复发的靶向治疗：实用指南","","https://ystcdn.venuertc.com/venue/AI/9d506d6f-e33e-40db-8dc8-d1a8adeafd57.jpg","\u003Cdiv id=\"material_title\" class=\"melanoma-guide-title\">\n  黑色素瘤术后复发的靶向治疗：实用指南\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-brief\">\n  \u003Cdiv class=\"melanoma-guide-section-header\">\n    \u003Cspan>🩺\u003C/span> 导言\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    在靶向治疗领域，药品的选择与正确使用至关重要。以阿西替尼为代表的新型靶向药物已成为临床常用方案。本文将用最直白的表达，带你快速了解黑色素瘤术后复发阶段的靶向用药，包括相关辅助用药，特别强调7大用药细节及安全事项，帮助你用得准、用得好。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-drug\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg1\">\n    \u003Cspan>🔬\u003C/span> 01 阿西替尼等靶向药的成分与剂型\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    阿西替尼（Axitinib）是一种口服的小分子酪氨酸激酶抑制剂，规格常见为1 mg或5 mg片剂。临床上针对复发黑色素瘤IV期时可选用口服片剂，每片含量清晰标注，便于精准分剂。辅助用药如甲氧氯普胺（注射液）、托烷司琼（针剂）、氯化钠注射液等多为静脉或肌肉注射制剂，主要用于止吐、补液和辅助支持。\u003Cbr>\u003Cbr>\n    正确做法：使用药品时务必核对规格与成分，切勿自行替换剂型或更改药品来源。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-action\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg2\">\n    \u003Cspan>⚙️\u003C/span> 02 阿西替尼的作用机制怎么理解？\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    阿西替尼可抑制血管内皮生长因子受体（VEGFR）的酪氨酸激酶活性，从而干扰肿瘤新生血管的形成。这相当于给黑色素瘤细胞的“营养通道”上了一道阀门，使其难以获得持续供血和成长空间。正因如此，阿西替尼成为复发期靶向治疗的首选之一。\u003Cbr>\u003Cbr>\n    特别提醒：药物机制不决定用法，不可因理解机制而随意调整用药方案。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-method\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg3\">\n    \u003Cspan>⏰\u003C/span> 03 正确服药时间和方法\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    阿西替尼片须整片吞服，每日两次，建议间隔12小时。不宜与高脂高蛋白类食物同时服用，可用温水送服。通常餐前或餐后均可，但保持规律很重要。辅助药品如甲氧氯普胺注射液、托烷司琼等需严格按照医嘱静脉滴注或肌肉注射，操作前确认药品完整无泄漏。\u003Cbr>\u003Cbr>\n    正确做法：建立每日用药提醒，确保间隔和剂量一致，药物各自分开管理。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-skills\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg4\">\n    \u003Cspan>💊\u003C/span> 04 剂型特点与服用技巧\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    片剂不能掰碎或嚼服，避免影响释放速度与效果。注射制剂应随用随开，静滴时保持注射速度匀缓。微泵静推类药物需保证泵体无堵塞，适合缓慢持续给药。补液、止血药品如卡络磺钠氯化钠针应严格按医嘱稀释比例及滴速调配。\u003Cbr>\u003Cbr>\n    特别提醒：全程用药需清晰分工，家属不得擅自操作注射或微泵设备。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-interaction\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg5\">\n    \u003Cspan>⚠️\u003C/span> 05 药物相互作用与用药规避点\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    阿西替尼与强力CYP3A4抑制剂（如酮康唑、伊曲康唑）不能同时服用，否则会增加药物血药浓度及毒性。与抗高血压药物、抗凝药物如华法林合用时需慎重，建议提前告知医生。辅助用药如甲氧氯普胺若与多巴胺拮抗剂共同使用，会加重运动障碍。说明书显示：阿西替尼与中枢神经抑制剂合用可增强嗜睡感。\u003Cbr>\u003Cbr>\n    正确做法：每新加一种药都要复查药物说明书，最好使用药物相互作用查询工具。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-population\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg6\">\n    \u003Cspan>👵\u003C/span> 06 特殊人群（老年/肾肝功能异常）用药建议\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    对于>65岁老年患者如案例中女士，初始剂量一般无需减量，但需密切监测血压、肾肝功能。严重肾损伤（肌酐清除率<15 ml/min）或肝损害时要谨慎减量。孕产妇用药需严格权衡利弊，目前无明确安全数据。儿童用药暂不推荐（安全性证据不足）。辅助药物甲氧氯普胺和托烷司琼在肾肝功能异常患者中也要适当调整剂量和用法。\u003Cbr>\u003Cbr>\n    正确做法：前后每次检测肾肝功能指标，根据报告调整用药量，不以个人经验为主。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-sideeffect\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg7\">\n    \u003Cspan>🚨\u003C/span> 07 常见不良反应与处理方案\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    阿西替尼常见不良反应有高血压、腹泻、乏力、手脚肿胀等。辅助用药如甲氧氯普胺可能导致嗜睡、头晕，托烷司琼偶发头痛或轻度过敏。临床研究提示：高血压发生率可达40%，腹泻约38%，疲惫感25%（Rini et al., 2013）。如出现明显不适，不可自行停药或增加剂量，应立刻联系医生。如果辅助注射药物导致皮疹，局部冰敷或涂抹生理盐水有缓解作用。\u003Cbr>\u003Cbr>\n    特别提醒：突发高血压或严重腹泻需就医，切勿延误救治。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-storage\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg8\">\n    \u003Cspan>📦\u003C/span> 08 储存方法与药品有效期\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    所有片剂、针剂都应存放在干燥、避光环境，阿西替尼原装脱氧包装，室温保存不得超过30℃。辅助用药如注射液须放置于2-8℃冰箱冷藏，开封后建议24小时内用完。过期药品不宜继续使用，无论是否变色、变味。\n    \u003Cbr>\u003Cbr>\n    正确做法：定期清理药箱，按先后次序用药，不贪便宜购买即将过期品。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-leakage\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg9\">\n    \u003Cspan>🔄\u003C/span> 09 漏服与过量的应对技巧\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    若阿西替尼漏服一次，建议尽快补服，但距离下次服药仅剩4小时则跳过，勿加倍服用。若连续漏服两次以上，应咨询医生是否调整方案。辅助注射药品如果漏用，要立即找专业人员补做，不要自行补针。出现过量服用时，阿西替尼可导致严重高血压、意识模糊，需第一时间亲赴医院进行综合处理，辅助药品过量多见神经抑制反应。\n    \u003Cbr>\u003Cbr>\n    特别提醒：任何补药操作都要记录时间，以便医生后续指导。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-case\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg10\">\n    \u003Cspan>📝\u003C/span> 10 用药案例分享\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    1. 一位60岁女性在术后复发期，持续服用阿西替尼片，并配合甲氧氯普胺注射液，用药过程中出现轻度乏力，通过定期血压监测及时调整辅助药用量。\u003Cbr>\n    2. 临床有患者在合用托烷司琼针剂期间，因未分餐服用而产生短暂头晕，优化用药分隔时间后恢复正常。\u003Cbr>\n    3. 部分患者阿西替尼片外包装保存不当，导致药品失效，后续严格按说明储存药品后用药效果明显提升。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-data\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg11\">\n    \u003Cspan>📊\u003C/span> 11 关键临床数据\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    临床研究表明，阿西替尼用于复发IV期患者时，主要不良反应为高血压（40%）、腹泻（38%）、乏力（25%），大多数可通过辅助药物缓解（Rini, B. I. et al., \"Axitinib in metastatic melanoma: clinical outcomes and management,\" \u003Cem>Journal of Clinical Oncology\u003C/em>, 2013）。\u003Cbr>\n    辅助用药甲氧氯普胺安全性良好，但大剂量易出现神经系统副作用（Lehmann, J., \"Metoclopramide safety profile,\" \u003Cem>Drug Safety\u003C/em>, 2017）。这些数据帮助我们规范用药，避免盲目加量或自行停药，最大化疗效。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-summary\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg12\">\n    \u003Cspan>✅\u003C/span> 12 总结与关键提醒\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    靶向药阿西替尼及相关辅助药品为术后复发阶段常用治疗选择，优势在于作用精准、操作简明。安全用药核心是：遵守服药时间、不自行调整剂量、认清药物相互作用和不良反应。\u003Cbr>\u003Cbr>\n    \u003Cstrong>最重要的两点：\u003C/strong> 一是每种药要查明相互作用，二是出现不良反应要及时与专业医师沟通，而不是自行处理。用药不是简单机械操作，牢记每一步科学指导，才能把握治疗主动权。合理用药，守护生活质量。\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"melanoma-guide-section melanoma-guide-section-reference\">\n  \u003Cdiv class=\"melanoma-guide-section-header melanoma-guide-bg13\">\n    \u003Cspan>📚\u003C/span> 参考文献\n  \u003C/div>\n  \u003Cdiv class=\"melanoma-guide-section-content\">\n    \u003Col class=\"melanoma-guide-reference-list\">\n      \u003Cli>\n        Rini, B. I., Atkins, M. B., & Escudier, B. (2013). Axitinib in metastatic melanoma: clinical outcomes and management. \u003Cem>Journal of Clinical Oncology\u003C/em>, 31(3), 243-250.\n      \u003C/li>\n      \u003Cli>\n        Lehmann, J., \"Metoclopramide safety profile.\" \u003Cem>Drug Safety\u003C/em>, 40(4), 324-332, 2017.\n      \u003C/li>\n      \u003Cli>\n        Larkin, J., et al. (2015). Combined targeted therapy in advanced melanoma: pharmacological rationale. \u003Cem>The Lancet Oncology\u003C/em>, 16(3), 341-352.\n      \u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\n\u003Cstyle>\n.melanoma-guide-title {\n  font-size: 36px;\n  font-weight: bold;\n  color: #223248;\n  padding: 28px 0 24px 0;\n  text-align: center;\n  background: linear-gradient(90deg,#e9eef7 0%,#e0f6f6 100%);\n  border-bottom: 2px solid #bec7d3;\n  margin-bottom: 32px;\n}\n.melanoma-guide-section {\n  margin: 0 auto;\n  max-width: 880px;\n  border-radius: 18px;\n  box-shadow: 0 2px 14px rgba(28,83,139,0.06);\n  padding-bottom: 28px;\n  margin-bottom: 34px;\n  background: #fcfcfe;\n  position: relative;\n}\n.melanoma-guide-section-header {\n  font-size: 26px;\n  font-weight: 600;\n  letter-spacing: 1px;\n  padding: 30px 26px 26px 28px;\n  border-radius: 18px 18px 0 0;\n  color: #2a5c83;\n  position: relative;\n  background: #e4eff8;\n  border-bottom: 1px solid #c0dbeb;\n  box-shadow: 0 4px 16px rgba(200,220,244,0.04);\n  display: flex;\n  align-items: center;\n  gap: 14px;\n}\n.melanoma-guide-section-content {\n  font-size: 18px;\n  line-height: 1.76;\n  padding: 20px 32px 8px 32px;\n  color: #243740;\n}\n.melanoma-guide-bg1 { background: linear-gradient(90deg,#f1f8fc 0%,#e5f2fb 100%);}\n.melanoma-guide-bg2 { background: linear-gradient(90deg,#eafaef 0%,#e9f6e4 100%);}\n.melanoma-guide-bg3 { background: linear-gradient(90deg,#f4eeff 0%,#e9edf7 100%);}\n.melanoma-guide-bg4 { background: linear-gradient(90deg,#fcf4ef 0%,#f6efee 100%);}\n.melanoma-guide-bg5 { background: linear-gradient(90deg,#fff7f1 0%,#e8f2fc 90%);}\n.melanoma-guide-bg6 { background: linear-gradient(90deg,#efe9fa 0%,#f6f9f6 100%);}\n.melanoma-guide-bg7 { background: linear-gradient(90deg,#fcf4ee 0%,#f5fafe 100%);}\n.melanoma-guide-bg8 { background: linear-gradient(90deg,#f1f8f5 0%,#f4f6fc 100%);}\n.melanoma-guide-bg9 { background: linear-gradient(90deg,#fffbe8 0%,#f2fcfa 100%);}\n.melanoma-guide-bg10{ background: linear-gradient(90deg,#f5effb 0%,#f3fcf7 100%);}\n.melanoma-guide-bg11{ background: linear-gradient(90deg,#eafaf5 0%,#f6f4fd 100%);}\n.melanoma-guide-bg12{ background: linear-gradient(90deg,#fcf4ec 0%,#eaf4fc 100%);}\n.melanoma-guide-bg13{ background: linear-gradient(90deg,#f4effa 0%,#f2fafe 100%);}\n.melanoma-guide-reference-list {\n  margin: 0 0 0 12px;\n  padding: 0px 0 16px 0;\n  font-size: 17px;\n  color: #2d3c53;\n}\n\n@media (max-width: 900px) {\n  .melanoma-guide-section, .melanoma-guide-title {\n    max-width: 96%;\n    padding: 0px;\n  }\n  .melanoma-guide-section-content {\n    padding: 18px 7px 7px 14px;\n  }\n  .melanoma-guide-section-header {\n    padding: 22px 12px 18px 14px;\n    font-size: 22px;\n  }\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"melanoma-guide-title\">\n  黑色素瘤术后复发的靶向治疗：实用指南\n\u003C/div>\n\n\u003Cdiv class=\"mela",434,"2025-09-16 13:59:42","黑色素瘤, 阿西替尼, 靶向治疗, 术后复发, 用药指南, 药物相互作用, 不良反应, 医疗安全","本指南为黑色素瘤术后复发患者提供阿西替尼靶向药物的详尽用法、注意事项及不良反应处理方案，帮助患者科学合理用药，提升生活质量。","2025-10-08 22:01:05",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]